|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 | |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
Geron Corporation Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... site, of telomerase. It focuses on oligonucleotides, called imetelstat sodium (originally known as GRN163L). It demonstrated ... cellular systems and animal studies. Imetelstat sodium (imetelstat) is a 13-mer oligonucleotide N3-- P5 thiophosphoramidate ( ... Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important ... Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H1 2018 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H1 2018 SUMMARY Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase ... Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2018 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2018 SUMMARY Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase ... Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma 2014 will be marked as a transition year for the Japanese Pharma industry - the year is bound to be painful both for innovators and generic companies due to the new regulations. We find these regulations to be 'decisive' in spurring generic penetration ... Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth (Status and Outlook) 2025-2031 ... ) to tumors and metabolic diseases. Geron's Imetelstat was approved as the first telomerase ... Global Oligonucleotide Therapy Market - 2025 -2033 ... . A landmark approval in 2024 was Rytelo (imetelstat), an oligonucleotide telomerase inhibitor for myelodysplastic ... Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review ... the development and commercialization of imetelstat, a first-in-class telomerase inhibitor ... intermediate or high-risk myelofibrosis. Imetelstat received Fast Track designation ... chemistry for the development of imetelstat. Geron is headquartered in Menlo Park ... |